Skip to content

Study · Animal study (in vivo) · mouse · 2017

18 results

The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.

Vinué Á, Navarro J, Herrero-Cervera A, García-Cubas M, Andrés-Blasco I, Martínez-Hervás S, Real JT, Ascaso JF, González-Navarro H

Diabetologia12 Jun 2017Cited by 118 (Europe PMC)

PMID28608285 (opens in a new tab)DOI10.1007/s00125-017-4330-3 (opens in a new tab)PepBankPUB-28608285
Source linkPubMedAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

18 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, liraglutide improved glucose metabolism independently of body weight loss.

    In plain wordsIn mice, liraglutide improved glucose metabolism independently of weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlucose metabolism
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment of Apoe -/- Irs2 +/- mice with either lixisenatide or liraglutide improved glucose metabolism and blood pressure but this was independent of body weight loss.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide improved glucose metabolism independently of body weight loss.

    In plain wordsIn mice, lixisenatide improved glucose metabolism independently of weight loss.

    Peptide
    Lixisenatide
    Outcome
    IncreaseGlucose metabolism
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment of Apoe -/- Irs2 +/- mice with either lixisenatide or liraglutide improved glucose metabolism and blood pressure but this was independent of body weight loss.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, liraglutide improved blood pressure independently of body weight loss.

    In plain wordsIn mice, liraglutide improved blood pressure independently of weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood pressure
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment of Apoe -/- Irs2 +/- mice with either lixisenatide or liraglutide improved glucose metabolism and blood pressure but this was independent of body weight loss.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide improved blood pressure independently of body weight loss.

    In plain wordsIn mice, lixisenatide improved blood pressure independently of weight loss.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBlood pressure
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment of Apoe -/- Irs2 +/- mice with either lixisenatide or liraglutide improved glucose metabolism and blood pressure but this was independent of body weight loss.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, liraglutide significantly decreased atheroma plaque size.

    In plain wordsIn mice, liraglutide reduced artery plaque size.

    Peptide
    Liraglutide
    Outcome
    DecreaseAtheroma plaque size
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both drugs significantly decreased atheroma plaque size.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide significantly decreased atheroma plaque size.

    In plain wordsIn mice, lixisenatide reduced artery plaque size.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAtheroma plaque size
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both drugs significantly decreased atheroma plaque size.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide generated more stable atheromas than vehicle.

    In plain wordsIn mice, lixisenatide produced more stable artery plaques than vehicle.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAtheroma stability
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Comparator
    Vehicle-treated controls
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with vehicle-treated control mice, lixisenatide treatment generated more stable atheromas, with fewer inflammatory infiltrates, reduced necrotic cores and thicker fibrous caps.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide reduced atheroma inflammatory infiltrates versus vehicle.

    In plain wordsIn mice, lixisenatide reduced inflammatory cells in artery plaques compared with vehicle.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAtheroma inflammatory infiltrates
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Comparator
    Vehicle-treated controls
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with vehicle-treated control mice, lixisenatide treatment generated more stable atheromas, with fewer inflammatory infiltrates, reduced necrotic cores and thicker fibrous caps.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide reduced atheroma necrotic cores versus vehicle.

    In plain wordsIn mice, lixisenatide reduced dead tissue inside artery plaques compared with vehicle.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAtheroma necrotic cores
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Comparator
    Vehicle-treated controls
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with vehicle-treated control mice, lixisenatide treatment generated more stable atheromas, with fewer inflammatory infiltrates, reduced necrotic cores and thicker fibrous caps.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide increased atheroma fibrous cap thickness versus vehicle.

    In plain wordsIn mice, lixisenatide thickened fibrous caps on artery plaques compared with vehicle.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAtheroma fibrous caps
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Comparator
    Vehicle-treated controls
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with vehicle-treated control mice, lixisenatide treatment generated more stable atheromas, with fewer inflammatory infiltrates, reduced necrotic cores and thicker fibrous caps.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide diminished IL-6 levels.

    In plain wordsIn mice, lixisenatide reduced IL-6 levels.

    Peptide
    Lixisenatide
    Outcome
    DecreaseIL-6 levels
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lixisenatide-treated mice also displayed diminished IL-6 levels, proinflammatory Ly6Chigh monocytes and activated T cells.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide diminished proinflammatory Ly6Chigh monocytes.

    In plain wordsIn mice, lixisenatide reduced proinflammatory monocytes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseProinflammatory Ly6Chigh monocytes
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Immune response · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lixisenatide-treated mice also displayed diminished IL-6 levels, proinflammatory Ly6Chigh monocytes and activated T cells.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In insulin-resistant mice, lixisenatide diminished activated T cells.

    In plain wordsIn mice, lixisenatide reduced activated T cells.

    Peptide
    Lixisenatide
    Outcome
    DecreaseActivated T cells
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Immune response · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lixisenatide-treated mice also displayed diminished IL-6 levels, proinflammatory Ly6Chigh monocytes and activated T cells.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In insulin-resistant mice, lixisenatide increased atheroma arginase I content.

    In plain wordsIn mice, lixisenatide increased arginase I in artery plaques.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAtheroma arginase I content
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, atheromas from lixisenatide-treated mice showed higher arginase I content and decreased expression of inducible nitric oxide synthase, indicating the prevalence of the M2 phenotype within plaques.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In insulin-resistant mice, lixisenatide decreased inducible nitric oxide synthase expression in atheromas.

    In plain wordsIn mice, lixisenatide reduced inducible nitric oxide synthase expression in artery plaques.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAtheroma inducible nitric oxide synthase expression
    Study

    mousen: not reported in source

    Apoe -/- Irs2 +/- mice
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, atheromas from lixisenatide-treated mice showed higher arginase I content and decreased expression of inducible nitric oxide synthase, indicating the prevalence of the M2 phenotype within plaques.
    1 context sentence
    Summary · context
    Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide.
  16. 16LabIn vitro (cells)Mechanism

    In mouse macrophages, lixisenatide reduced IL-6 secretion.

    In plain wordsIn cells from mice, lixisenatide reduced IL-6 secretion.

    Peptide
    Lixisenatide
    Outcome
    DecreaseMacrophage IL-6 secretion
    Study

    mousen: not reported in source

    Macrophages from Apoe -/- Irs2 +/- mice
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro analysis showed that, in macrophages from Apoe -/- Irs2 +/- mice, lixisenatide reduced the secretion of the proinflammatory cytokine IL-6 accompanied by enhanced activation of signal transducer and activator of transcription (STAT) 3, which is a determinant for M2 macr…
  17. 17LabIn vitro (cells)Mechanism

    In mouse macrophages, lixisenatide enhanced STAT3 activation.

    In plain wordsIn cells from mice, lixisenatide increased STAT3 activation.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSTAT3 activation
    Study

    mousen: not reported in source

    Macrophages from Apoe -/- Irs2 +/- mice
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro analysis showed that, in macrophages from Apoe -/- Irs2 +/- mice, lixisenatide reduced the secretion of the proinflammatory cytokine IL-6 accompanied by enhanced activation of signal transducer and activator of transcription (STAT) 3, which is a determinant for M2 macr…
  18. 18LabIn vitro (cells)Mechanism

    In mouse macrophages, lixisenatide diminished STAT1 activation.

    In plain wordsIn cells from mice, lixisenatide reduced STAT1 activation.

    Peptide
    Lixisenatide
    Outcome
    DecreaseSTAT1 activation
    Study

    mousen: not reported in source

    Macrophages from Apoe -/- Irs2 +/- mice
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    STAT1 activation, which is essential for M1 phenotype, was also diminished.
    1 context sentence
    Summary · context
    In vitro analysis showed that, in macrophages from Apoe -/- Irs2 +/- mice, lixisenatide reduced the secretion of the proinflammatory cytokine IL-6 accompanied by enhanced activation of signal transducer and activator of transcription (STAT) 3, which is a determinant for M2 macr…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT04137328

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Fudan Universityn = 60est. 30 Nov 2019 to est. 30 Nov 2022

Diabetic Neuropathic Pain

Trial pageClinicalTrials.govUpdated 25 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.